Monopar Therapeutics (MNPR) Profit After Tax Growth (5y) (2022 - 2025)

Monopar Therapeutics (MNPR) Profit After Tax Growth (5y) (2022 - 2025) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Monopar Therapeutics 800.03 Mn 738.20 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2025 -16.42%
Jun 30, 2025 -11.16%
Mar 31, 2025 -19.20%
Sep 30, 2024 -11.86%
Jun 30, 2024 -13.62%
Mar 31, 2024 -3.58%
Sep 30, 2023 -25.04%
Jun 30, 2023 -28.00%
Mar 31, 2023 -22.67%
Dec 31, 2022 -32.23%
Sep 30, 2022 30.72%
Jun 30, 2022 -36.11%
Mar 31, 2022 -45.80%